Welcome to the Medical Faculty of the University of Bonn
We are 1 of 7 faculties of the University of Bonn and affiliated to the transdisciplinary research area Life and Health. We maintain extensive partnerships with institutions of the Helmholtz Association, the Max Planck Society, and national and international research associations in the life sciences.
We are committed to outstanding, nationally and internationally visible translational research from basic sciences to patient care, as well as to teaching and training students closely linked to science to become competent and empathetic physicians.
Both tasks are fulfilled in close cooperation with the University Hospital and with respect for our employees.
Every year some 75,000 people die from bacterial blood poisoning, or sepsis, in Germany alone. Survivors of sepsis often struggle with secondary and concomitant conditions due to the resulting impairment of the immune system, the so called “Immunesuppression”. The International Center for Clinical Research (ICRC) at St. Anne's University Hospital (FNUSA) Brno (Czech Republic) has founded the research consortium “BEATSep”. HORIZON EUROPA is funding it with around 6,9 million euros over the next five years. The project aims to study the cellular and molecular mechanisms causing the immune suppression in sepsis survivors. Prof. Dr. Bernardo S. Franklin, Institute for Innate Immunity of the University Hospital Bonn and member of the ImmunoSensation2 Cluster of Excellence of the University of Bonn, is involved in the project. He receives about 800,000 euros from the EU funding.
A great many criteria determine whether or not we get seriously ill from COVID-19. Besides our age and any previous or existing conditions, they also include genetic factors. Right from the start of the pandemic, the “COVID-19 Host Genetics Initiative” has been investigating the links between genetic factors and severe COVID-19. The international research consortium has now discovered 28 new risk factors, pushing the total number of candidate genes identified by the initiative up to 51. Its findings have now been published in the prestigious journal “Nature.”
How are bacteria on our mucous membranes affected by type-A antibodies (IgA)? Assistant professor Dr. Tim Rollenske works at University Hospital Bonn to study specific immune system effects on the intestinal tract. Dr. Rollenske is leader of an Emmy Noether Research Group newly formed at the University of Bonn, which he believes will open the door to a professorship. The German Research Foundation (DFG) will be providing up to two million euros in funding for the project over the next six years. The research results could lead to more effective vaccination strategies for the mucous membranes and support efforts to counter antibiotic-resistant bacteria.
More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the world are searching for new effective substances. Researchers from the University of Bonn, the German Center for Infection Research (DZIF), Utrecht University (Netherlands), Northeastern University in Boston (USA) and the company NovoBiotic Pharmaceuticals in Cambridge (USA) now have discovered and deciphered the mode of action of a new antibiotic. Clovibactin is derived from a soil bacterium. This antibiotic is highly effective at attacking the cell wall of bacteria, including many multi-resistant “superbugs.” The results have now been published in the renowned journal “Cell.”
Certificates
